Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2009

View Archived Issues

Novel proteasome inhibitors claimed by Millennium Pharmaceuticals

FX-06 limits infarct size in myocardial infarction

CSA-13 exhibits potent bactericidal activity against cariogenic and periodontopathic bacteria

FDA approves Insmed's Iplex for ALS under IND applications

PolyMedix reports results from first-in-man phase I clinical study of PMX-60056

Roche and Genentech agree to merge

FDA approves expanded indication for peginterferon-based combination therapy

Gilead Sciences to acquire CV Therapeutics

AGI announces results from phase II AGI-004 proof-of-concept study

Sutent increases progression-free survival in advanced pancreatic islet cell tumors

Phase III Rituxan study did not meet primary endpoint in lupus nephritis

Dimebolin safe, improves cognition in Huntington's disease patients

Preliminary findings suggest AD-01, AD-02 vaccines are safe in Alzheimer's disease patients

FDA approves Molecular Insight's SPA for phase II registration trial of Azedra

Topical INCB-018424 displays safety and efficacy in patients with psoriasis

QLT completes phase Ia safety trial of QLT-091001 in healthy volunteers

InteKrin completes enrollment in phase IIb study of INT-131 in type 2 diabetes

Ono and Xention sign drug discovery agreement targeting ion channels

Novel skin protease inhibitors may provide new treatment for atopic dermatitis

Oncophage cancer vaccine receives positive orphan drug recommendation

Takeda launches Ecard in Japan

Uloric now available for hyperuricemia in patients with gout

Novel activators of glucokinase developed by Metabasis Therapeutics

Neurogen presents novel heteroaryl amide analogues

Novel beta-secretase inhibitors claimed by CoMentis and Purdue Research Foundation

Novartis presents novel GABA-A receptor ligands

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...